[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Liverpool University Hospitals NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":192},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,73,100,128,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100636054","feasibility-of-web-based-therapy-sessions-100636054",false,"NCT07560696","Feasibility of Web-based Therapy Sessions","A Feasibility Study to Explore Rehabilitation Outcomes, Usability and User Experience of a Web-Based Platform for Delivering Treatment for Cognitive and Language Impairment Amongst Adults With Acquired Neurological Disorders","Cognishine","Inclusion Criteria:\n\n* Patients with cognitive impairment and\u002For speech impairment being treated at the LUHFT Intensive Care Units and the Stroke wards\n* Need for Cognitive and\u002For speech and Language rehabilitation\n\nExclusion Criteria:\n\n* Inability to obtain consent\n* Refusal to take part in the study\n* Failure to engage with the Cognishine platform\n* Inability to operate a mobile device\u002F tablet with support\n* Unavailability of study therapist to provide training of patients\n* Unstable medical condition","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this feasibility study is to explore rehabilitation outcomes, usability and user experience of a web-based platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders in critical illness and stroke disorders.\n\nThe main question it aims to answer is:\n\n\" Is it feasible to use a web-based platform for delivering rehabilitation treatment in a large acute National Health Care Organisation\"\n\nParticipants will undergo therapy sessions prescribed by therapists on a web-based platform instead of the conventional paper-based therapy sessions for their cognitive and speech rehabilitation needs.",[27,28,29],"Cognitive Impairment","Speech Dysfunction","Acquired Brain Injury","RECRUITING","2026-04-28",{"date":33,"type":34},"2026-05-01","ACTUAL",{"date":36,"type":34},"2024-07-03",{"date":38,"type":21},"2026-07-01",{"name":40,"class":41},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100623047","achilles-tendon-rupture-patient-outcomes-at-12-months-100623047","NCT07391553","Achilles Tendon Rupture Patient Outcomes at 12 Months","What Are the Isokinetic Strength Outcomes and Self-reported Functional Outcomes (ATRS) at 12 Months Following Non-surgical Management of Achilles Tendon Rupture Using the SMART Protocol?","ATR-12","Inclusion Criteria:\n\n* Adults aged 18 years or older at the time of recruitment.\n* Confirmed diagnosis of Achilles tendon rupture, diagnosed clinically and recorded within the NHS database.\n* Injury managed non-surgically using the SMART (Swansea Morriston Achilles Rupture Treatment) protocol.\n* 12-15 months post-injury at the time of assessment.\n* Able and willing to provide informed written consent to participate in the study.\n\nExclusion Criteria:\n\n* Unable to provide informed consent.\n* Previous surgical repair of the Achilles tendon or documented re-rupture.\n* Presence of a neuromuscular disorder affecting lower limb strength or function.\n* Did not follow the SMART protocol for non-surgical management.\n* History of Achilles tendinopathy or rupture in the contralateral (uninjured) leg.\n* Unable to tolerate isokinetic strength testing due to pain, discomfort, or other medical reasons.",{"count":52,"type":21},115,"OBSERVATIONAL","The Achilles tendon is the strongest and largest tendon in the human body, playing a critical role in plantarflexion and facilitating activities such as walking, running, and jumping. However, it is also the most frequently ruptured tendon. The injury and associated disability have a significant impact on patient quality of life and healthcare services. Achilles tendon ruptures are increasingly common, particularly among middle-aged recreational athletes, with an incidence estimated at 18 per 100,000 person-years.\n\nThe Swansea Morriston Achilles Rupture Treatment (SMART) protocol represents a structured, progressive approach to non-operative rehabilitation. It emphasizes early mobilization, protected weight-bearing, and a gradual return to sport or high-level function through targeted strength and neuromuscular training. While short-term outcomes of non-surgical protocols have demonstrated promising results, there remains limited high-quality data on long-term isokinetic strength and patient-reported functional outcomes beyond six months in this patient group.\n\nThis study aims to evaluate isokinetic plantarflexor strength and self-reported functional outcomes at 12 months following non-surgical management of Achilles tendon ruptures using the SMART rehabilitation protocol. By assessing both objective and subjective recovery metrics, we aim to contribute to the growing evidence base for evidence-informed, conservative Achilles tendon rehabilitation. A secondary aim of the study is to examine the relationship between isokinetic strength scores and self reported functional recovery scores using the ATRS questionnaire.\n\nParticipants will attend one 60-90 minute visit to complete a short questionnaire and perform a safe, clinic-based ankle strength test using an isokinetic machine; the test feels like pushing against a footplate, similar to resisted ankle movements. The results of these tests will be collected and analysed. The study will help to gain further insight into patient recovery from this injury.",[56],"Achilles Tendon Rupture",[58,59,60,61,62],"Achilles tendon rupture","Physiotherapy","orthopaedics","trauma","rehabilitation","NOT_YET_RECRUITING","2026-02-27",{"date":66,"type":34},"2026-03-03",{"date":68,"type":21},"2026-06-01",{"date":70,"type":21},"2029-01-01",{"name":40,"class":41},2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100595593","air-tamponade-versus-fluorinated-gas-tamponade-for-rhegmatogenous-retinal-detachment-100595593","NCT07034469","Air Tamponade Versus Fluorinated Gas Tamponade for Rhegmatogenous Retinal Detachment","Gas Tamponade Versus Air During Vitrectomy for Rhegmatogenous rEtinal dEtachmeNt; a Randomised Controlled Trial","GREEN","Inclusion Criteria:\n\n* Primary uncomplicated RRD undergoing vitrectomy.\n* Phakic and pseudophakic eyes\n* Retinal breaks superiorly between 3 and 9 o'clock, and that are separated by less than 4 clock hours.\n\nExclusion Criteria:\n\n* Absence of PVD\n* Age 40 years or younger\n* PVR grade C or above\n* Aphakia or anterior chamber lens\n* Retinal breaks greater than 1 clock hour in size\n* Retinal breaks that exist below 3 and 9 o'clock on both the nasal and temporal sides.\n* Retinal breaks at or posterior to the vessel arcades\n* Current or previous -6D myopia or greater (or axial length \\>26millimetres (mm))\n* Chronic RRD judged by the presence of subretinal bands and other signs of -chronicity or by history of visual loss for \\>28 days.\n* Significant inflammation, choroidal detachments, hypotony (\\\u003C6 millimetres of mercury (mmHg) preop)\n* Previous open-globe injury, or endophthalmitis\n* Current or previous posterior uveitis or choroiditis\n* Any intraocular surgical procedure within 4 weeks other than laser\u002Fcryotherapy\n* Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol.","40 Years",{"count":83,"type":21},150,[24],"TITLE: RCT of air tamponade versus fluorinated gas tamponade for rhegmatogenous retinal detachment DESIGN: Non-inferiority RCT of 150 patients from 10 UK centres AIMS: To assess whether air tamponade is non inferior to gas tamponade for the repair of RRD treated with vitrectomy.\n\nPRIMARY OUTCOME MEASURE: Primary anatomical success with single operation at 24 weeks.",[87],"Retinal Detachment Rhegmatogenous",[89,90,91],"retinal detachment","gas tamponade","air","2025-12-18",{"date":94,"type":34},"2025-12-24",{"date":96,"type":21},"2026-03-20",{"date":98,"type":21},"2029-03-20",{"name":40,"class":41},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":42},"100559631","safety-tolerability-and-performance-of-the-nucleocapture-extracorporeal-therapeutic-apheresis-device-in-the-reduction-of-circulating-cfdnanets-in-subjects-with-pancreatitis-100559631","NCT06566638","Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA\u002FNETs in Subjects With Pancreatitis","NUC-SAP1","Inclusion Criteria:\n\n1. Adult patients aged 18 or over\n2. Acute pancreatitis (following revised Atlanta definition of 2 out of typical pain, serum amylase \\>3x normal range and\u002For CT\u002FMRI imaging consistent with pancreatitis)\n3. Any aetiology\n4. Acute respiratory (PaO2\u002FFiO2 \\\u003C300), cardiovascular (systolic BP \\\u003C90 or any inotropic therapy) or renal failure (serum creatinine \\>170 µmol\u002Fl, or deterioration of \\>50% eGFR if pre-existing renal disease or urine output \\\u003C0.5ml\u002Fkg\u002Fhr for 3 consecutive hours) presenting at any point during the index admission and persistent after 12 h of fluid resuscitation, but for not more than 72 hours\n5. Have provided written informed consent or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law).\n\n   Exclusion Criteria:\n6. The use of other non-routine extracorporeal treatments such as very high flux renal replacement therapy (\\>60ml\u002Fkg\u002Fh total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc).\n7. Presence of severe multiple organ failure at the point of enrolment as evidenced by:\n\n   * Severe refractory vasoplegic failure\n\n     * Norepinephrine dose \\> 0.60 μg\u002Fkg\u002Fmin\n     * Use of epinephrine\n   * Concomitant cardiogenic shock, clinically suspected or cardiac index \\\u003C2.2 L\u002Fmin\u002Fm2 if measured\n\n     * Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan\n   * Coagulopathy as defined by Platelet count \\\u003C50x10\\^9\u002FL\n8. Calculated Plasma Volume greater than 5000ml as determined by the following formula:\n\n   Vplasma = Vblood x (1 - haematocrit)\n\n   Where:\n\n   Vplasma = PV Vblood = an estimation of total blood volume (TBV; according to Nadler's formula, incorporating height, weight and sex).\n\n   A TBV calculator is available at https:\u002F\u002Fwww.omnicalculator.com\u002Fhealth\u002Fblood-volume\n9. Known liver cirrhosis (histologically proven or clinically suspected)\n10. Active bleeding\n11. Known citrate intolerance if citrate is required for therapeutic apheresis\n12. Known heparin allergy if heparin is required for therapeutic apheresis\n13. Known metastatic disease with life expectancy of \\\u003C12 months and ECOG score of at least 2\n14. Known haematological malignancy if not in remission\n15. Known solid organ transplant and concomitant use of immunosuppression\n16. Known long term oxygen therapy or Home oxygen use\n17. Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D)\n18. Planned or impending dialysis\n19. Prior use of cardiopulmonary resuscitation (CPR) in current admission\n20. Requirement for extracorporeal membrane oxygenation (ECMO)\n21. Patient expected to die within 48 hours of admission to ICU\n22. Known allergy to components of NucleoCapture (Sepharose beads and linker histone H1.3)\n23. Pre-existing disease of the exocrine pancreas including chronic pancreatitis, recurrent acute pancreatitis, pancreatic malignancy and\u002For history of pancreatic surgery\n24. Chronic neuromuscular disease affected breathing\n25. Current Participation in another interventional clinical study\n26. Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)",{"count":108,"type":21},20,[24],"This is a single-centre, randomised-controlled, open-label, feasibility study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)\u002FNeutrophil Extracellular Traps (NETs) in patients with severe acute pancreatitis.",[112,113],"Acute Pancreatitis","Organ Failure, Multiple",[115,116,117,118,119],"Acute pancreatitis","NucleoCapture","Extracorporeal","Apheresis","Neutrophil extracellular traps","2025-03-17",{"date":122,"type":34},"2025-03-20",{"date":124,"type":21},"2025-12-01",{"date":126,"type":21},"2027-04-01",{"name":40,"class":41},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":137,"conditions":138,"keywords":147,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":42},"100518030","expanding-the-scope-of-post-transplant-hla-specific-antibody-detection-and-monitoring-in-renal-transplant-recipients-100518030","NCT06025240","Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients","HLA-AB","Inclusion Criteria:\n\n1. cf-DNA arm:\n\n   * Adult patients transplanted within 6-12 months (retrospective recruitment)\n   * Patients admitted for renal transplant or within the first 6 months following transplant (prospective recruitment)\n   * Patients must have capacity to provide informed consent\n   * Patients must have received a high-risk transplant defined as level 4 mismatch, cRF \\>20, second or subsequent transplant, ABO or HLA incompatible\n2. Older Age Immunological Events:\n\n   \\- Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant\n3. Predictive models:\n\n   * Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant\n   * Unsensitized pre-transplant\n\nExclusion Criteria:\n\n1. cf-DNA arm:\n\n   * Transplanted for longer than 12 months;\n   * Low risk transplants;\n   * Patients lacking capacity;\n2. Older Age Immunological Events:\n\n   * Patients lacking capacity\n   * Patients transplanted longer than 2 weeks\n3. Predictive models:\n\n   * Sensitised patients\n   * Patients lacking capacity\n   * Patients transplanted longer than 2 weeks",{"count":136,"type":21},282,"The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.",[139,140,141,142,143,144,145,146],"Kidney Transplant","Renal Transplant Failure","Kidney Transplant Rejection","Frailty","Kidney Transplant; Complications","Transplant Dysfunction","Diagnosis","Renal Transplant",[148,149,150,151,152,153,154,155,156],"kidney transplant","novel biomarkers","post-transplant antibodies","HLA-specific antibodies","donor specific antibodies","transplant in older age","machine learning","predictive models","rejection","2024-08-28",{"date":159,"type":34},"2024-08-30",{"date":161,"type":34},"2023-10-13",{"date":163,"type":21},"2026-10-13",{"name":40,"class":41},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":172,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":4},"100518993","novel-cardiovascular-biomarkers-in-patients-with-kidney-disease-100518993","NCT06037759","Novel Cardiovascular Biomarkers in Patients With Kidney Disease","CBKD","Inclusion Criteria:\n\nPatients aged≥45 years (or ≥18 with a history of diabetes). b. Cases: Incident haemodialysis patients c. A comparative arm of peritoneal dialysis patients and CKD 3-4 (not on dialysis) with hypertension as a key risk factor for CVD.\n\nd. Capable of understanding the purpose and risks of the study, fully informed, and given informed consent.\n\nExclusion Criteria:\n\n1. Patients with pre-existing heart disease will be excluded.\n2. Patients with active cancer.",true,{"count":174,"type":21},100,"Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work as well as they should. End-stage kidney failure (ESKD) is the final, irreparable stage of chronic kidney disease (CKD), where kidney function has worsened, so the kidneys can no longer function independently.\n\nAt this stage, dialysis is required to remove waste products and excess fluid from the blood. There are two types of dialysis. In haemodialysis (HD), blood is pumped out of the body to an artificial kidney machine and returned to the body by tubes that connect a person to the machine. In peritoneal dialysis (PD), the inside lining of the belly acts as a natural filter. PD has the advantage of being gentler on the heart. HD causes significant stress to the heart by reducing the blood flow to the heart muscle, resulting in heart failure, irregular rhythms, and eventually sudden heart death. A large observational study showed that HD patients had 48% worse survival in the first two years than PD patients.\n\nSeveral molecules ('biomarkers') can be detected in blood and inform doctors of heart damage. Studying the form and function of proteins (Proteomics), including how they work and interact with each other inside cells in patients, could help identify the onset of heart problems. HD patients are also prone to body fat changes (cholesterol\u002Flipids). Due to high cholesterol, there is build-up on the walls of arteries, causing their hardening. In HD patients, this process is faster due to abnormalities in lipid structure. Therefore, studying the heart biomarkers, protein, and lipid makeup of HD patients may help to find people at substantial risk of heart and vascular problems and if they are likely to become unwell due to these heart problems.",[177,178],"Haemodialysis Complication","Major Adverse Cardiac Events",[180,181,182,183,178],"Chronic Kidney Disease","End Stage Kidney Disease","Haemodialysis","Biomarkers","2023-09-14",{"date":186,"type":34},"2023-09-18",{"date":188,"type":21},"2023-11-01",{"date":190,"type":21},"2026-11-01",{"name":40,"class":41},""]